Article Sidebar
Published:
Jan 17, 2025Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Inhibitory effect of PD173074 drug on DMBA-induced mammary carcinoma in female Swiss albino mice
Abstract
Purpose: To determine the effect of PD173074 on mammary carcinoma.
Methods: Virgin female mice were randomly divided into 4 groups of 10 mice per group. Group 1(control) received clean water, group 2 received an oral dose of 50 mg/kg PD173074 twice a week, group 3 received a single dose of 50 mg/kg 7,12-Dimethylbenz(a)anthracene (DMBA) in the breast for carcinoma induction, group 4 received DMBA and after that treated with PD173074 one week later for 4 weeks. Hormonal analysis, oxidative stress, levels of cytokines IL6 and TNF-α, and histopathological and immunohistochemical analysis were carried out.
Results: Treatment with PD173074 significantly lowered estrogen, progesterone, oxidative stress indices, cytokines IL6, and TNF-α levels (p < 0.05) raised due to carcinoma induction. Pyrido (2,3-d) pyrimidine derivative PD173074 lowered the Nottingham histopathological score and reduced the incidence of invasive ductal carcinoma. Furthermore, immunohistochemical analysis showed that posttreatment with PD173074 significantly decreased K167 expression (p < 0.05).
Conclusion: PD173074 significantly reduces estrogen, progesterone, oxidative stress indices, cytokines, TNF-α, Nottingham histopathological score, and KI-67 expression. Additional studies would be required to validate the actual mechanisms of this drug action.
